Dong-A St (170900) - Total Liabilities

Latest as of December 2025: ₩740.40 Billion KRW ≈ $501.76 Million USD

Based on the latest financial reports, Dong-A St (170900) has total liabilities worth ₩740.40 Billion KRW (≈ $501.76 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Dong-A St strategic investment ratio to see how much of total assets are deployed in long-term investments.

Dong-A St - Total Liabilities Trend (2013–2025)

This chart illustrates how Dong-A St's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Dong-A St (170900) total assets.

Dong-A St Competitors by Total Liabilities

The table below lists competitors of Dong-A St ranked by their total liabilities.

Company Country Total Liabilities
X3 Acquisition Corp. Ltd. Class A Ordinary Shares
NASDAQ:XCBE
USA $5.85 Million
NACCO Industries Inc
NYSE:NC
USA $248.54 Million
QORIA Ltd
AU:QOR
Australia AU$175.38 Million
Dimerco Data System
TWO:5403
Taiwan NT$2.60 Billion
Automatic Bank Services Ltd
TA:SHVA
Israel ILA48.05 Million
Chongqing Machinery & Electric Co. Ltd
F:CE3
Germany €10.65 Billion
Mkango Resources Ltd
V:MKA
Canada CA$14.81 Million
Kogan.com Ltd
AU:KGN
Australia AU$129.62 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Dong-A St's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 170900 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.52 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.15 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.52 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Dong-A St's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Dong-A St (2013–2025)

The table below shows the annual total liabilities of Dong-A St from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 ₩740.40 Billion
≈ $501.76 Million
+8.42%
2024-12-31 ₩682.93 Billion
≈ $462.81 Million
+17.52%
2023-12-31 ₩581.11 Billion
≈ $393.81 Million
+24.27%
2022-12-31 ₩467.61 Billion
≈ $316.90 Million
+1.74%
2021-12-31 ₩459.61 Billion
≈ $311.47 Million
+35.75%
2020-12-31 ₩338.57 Billion
≈ $229.44 Million
-6.71%
2019-12-31 ₩362.92 Billion
≈ $245.94 Million
-1.73%
2018-12-31 ₩369.31 Billion
≈ $250.28 Million
+15.94%
2017-12-31 ₩318.53 Billion
≈ $215.86 Million
-33.28%
2016-12-31 ₩477.40 Billion
≈ $323.52 Million
-6.35%
2015-12-31 ₩509.77 Billion
≈ $345.46 Million
-14.11%
2014-12-31 ₩593.52 Billion
≈ $402.22 Million
+20.55%
2013-12-31 ₩492.36 Billion
≈ $333.66 Million
--

About Dong-A St

KO:170900 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$225.15 Million
₩332.23 Billion KRW
Market Cap Rank
#16196 Global
#582 in Korea
Share Price
₩34450.00
Change (1 day)
-1.15%
52-Week Range
₩32000.00 - ₩57800.00
All Time High
₩155894.20
About

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more